Agios Pharmaceuticals, Inc. (AGIO) Stock Ticker
AGIO right now
Market factors today
Unlock the full AGIO picture
About Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research and advancement of new treatments, specifically targeting cellular metabolism and related biological fields. The company's offerings include PYRUKYND (mitapivat), a medication designed to activate both wild-type and various mutated pyruvate kinase (PK) enzymes, used in the management of hemolytic anemias. Additionally, Agios is developing AG-946, which is currently undergoing Phase I clinical studies for treating hemolytic anemias and other diseases. Established in 2007, the company's main office is located in Cambridge, Massachusetts.
AGIO stock facts
| Ticker symbol | AGIO |
| Exchange | NASDAQ Global Select |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $1.9B |
| CEO | Brian Goff |
| Employees | 540 |
| Headquarters | Cambridge, MA, US |
| IPO date | 2013-07-24 |
| Website | www.agios.com |
What you can see for AGIO on Tickr
Live AGIO price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the AGIO report.
Rankings
FAQ
What is the ticker symbol for Agios Pharmaceuticals, Inc.?
The ticker symbol for Agios Pharmaceuticals, Inc. is AGIO, listed on the NASDAQ Global Select.
What is AGIO?
Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research and advancement of new treatments, specifically targeting cellular metabolism and related biological fields. The company's offerings include PYRUKYND (mitapivat), a medication designed to activate both wild-type and various mutated pyruvate kinase (PK) enzymes, used in the management of hemolytic anemias.…